Effect of probiotic and zinc supplementation separately and in combination on reducing the complication of influenza-like syndrome during therapy by beta-interferon in patients with relapsing-remitting multiple sclerosis

Effect of probiotic and zinc supplementation separately and in combination on reducing the complication of influenza-like syndrome during therapy by beta-interferon in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N375

Enrollment

Registered

2021-01-22

Start date

2021-04-04

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsing-remitting multiple sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group 1: Beta-interferon-1a 30 micrograms once a week intramuscular and Beta-interferon-1b 250 micrograms every-other-day subcutaneously for 3 months plus tablet zinc oxid

Eligibility

Sex/Gender

All

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Age: 20 to 40 years old Relapsing-remitting multiple sclerosis Corticosteroid therapy for at least 3 weeks

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding, Receiving influenza vaccine Respiratory infection in the past 2 weeks, Using alcohol or opioid drugs in the past 2 months, Autoimmune diseases or immunodeficiency syndrome, Abdominal surgery, Short bowel syndrome, Mesenteric Ischemia, History of tuberculosis or AIDS, Liver or renal disease or diabetes or hypertension

Design outcomes

Primary

Measure	Time frame
Influenza-like syndrome. Timepoint: 3 months after intervention. Method of measurement: By history taking.	—

Secondary

Measure	Time frame
Gastrointestinal complications (nausea, vomiting, abdominal pain), headache and muscle aches, hot flashes, fever and fatigue. Timepoint: 3 months after intervention. Method of measurement: By history taking.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehran Fathi

Hamedan University of Medical Sciences

mehranfathi1717@gmail.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026